Title |
An economic evaluation of antihypertensive therapies based on clinical trials
|
---|---|
Published in |
Clinics, January 2012
|
DOI | 10.6061/clinics/2012(01)07 |
Pubmed ID | |
Authors |
Rosana Lima Garcia Tsuji, Giovanio Vieira da Silva, Katia Coelho Ortega, Otávio Berwanger, Décio Mion Júnior |
Abstract |
Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have been scarce. The cost-effectiveness ratios of the traditional treatment (hydrochlorothiazide and atenolol) and the current treatment (losartan and amlodipine) were evaluated in patients with grade 1 or 2 hypertension (HT1-2). For patients with grade 3 hypertension (HT3), a third drug was added to the treatment combinations: enalapril was added to the traditional treatment, and hydrochlorothiazide was added to the current treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Brazil | 1 | 2% |
Unknown | 49 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 16% |
Student > Bachelor | 7 | 14% |
Student > Ph. D. Student | 7 | 14% |
Researcher | 5 | 10% |
Student > Doctoral Student | 4 | 8% |
Other | 8 | 16% |
Unknown | 12 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 14% |
Economics, Econometrics and Finance | 4 | 8% |
Social Sciences | 2 | 4% |
Agricultural and Biological Sciences | 2 | 4% |
Other | 7 | 14% |
Unknown | 14 | 27% |